BioAdvance News

iVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis

By WebmasterJanuary 18, 2023November 1st, 2024No Comments

iVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis

Previous PostAnnovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Next PostRelmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors